News & Updates
Filter by Specialty:

Nonhormonal drug for hot flash scores big in two phase III trials
02 Nov 2024
byJairia Dela Cruz
The novel neurokinin-1 and -3 receptor antagonist elinzanetant appears to reduce the frequency and severity of vasomotor symptoms (VMS), as well as improve sleep and menopause-related quality of life, as shown in two pivotal phase III trials.
Nonhormonal drug for hot flash scores big in two phase III trials
02 Nov 2024
DISCREET highlights apremilast potential for genital psoriasis
22 Oct 2024
byAudrey Abella
Individuals with psoriasis creeping into their intimate areas may find relief from apremilast, as shown by the week-32 improvements in multiple disease parameters in the phase III DISCREET study.